Treatment outcomes of MDR-TB and HIV co-infection in Europe

Magis-Escurra Cecile; Gunther Gunar; Lange Christoph G.; Noi Autori; Ciobanu Ana; Krudu V.

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

246

SM ISO690:2012

MAGIS-ESCURRA, Cecile, GUNTHER, Gunar, LANGE, Christoph G., NOI, Autori, CIOBANU, Ana, KRUDU, V.. Treatment outcomes of MDR-TB and HIV co-infection in Europe. In: European Respiratory Journal, 2017, vol. 49, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.02363-2016

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

European Respiratory Journal

Volumul 49 / 2017 / ISSN 0903-1936 /ISSNe 1399-3003

Treatment outcomes of MDR-TB and HIV co-infection in Europe

DOI:https://doi.org/10.1183/13993003.02363-2016

Pag. 0-0

Magis-Escurra Cecile¹, Gunther Gunar², Lange Christoph G.²³⁴⁵, Noi Autori, Ciobanu Ana⁶, Krudu V.⁶

¹ Radboud University,
² German Centre for Infection Research (DZIF), Partner Site Hamburg-Luebeck-Borstel-Riems,
³ University of Namibia, School of Medicine, Windhoek,
⁴ University of Lübeck,
⁵ Karolinska Institutet, Stockholm,
⁶ Institute of Phtysiopneumology „Chiril Draganiuc”

Disponibil în IBN: 13 februarie 2023

Rezumat

The ongoing HIV epidemic and the increasing number of patients with drug-resistant tuberculosis (TB) are seriously hampering global TB-control activities, including those in the World Health Organization (WHO) Region Europe. Overall, the prevalence of HIV co-infection in TB patients increased from 3.4% in 2008 to 8% in 2014 in the region [1]. The prevalence of multidrug-resistant (MDR)-TB (drug resistance against at least isoniazid and rifampicin) reported for Europe – 15% in newly diagnosed TB patients and 48% in previously treated TB patients – is the highest in the world [1].

Cuvinte-cheie
Antitubercular Agents, Coinfection, Communicable Disease Control, data collection, Disease-Free Survival, Europe, Germany, HIV infections, Humans, Kaplan-Meier Estimate, Patient Outcome Assessment, prevalence, Proportional Hazards Models, Regression analysis, Risk, tuberculosis, Multidrug-Resistant

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-174121</cfResPublId>
<cfResPublDate>2017-06-01</cfResPublDate>
<cfISSN>0903-1936</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/174121</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Treatment outcomes of MDR-TB and HIV co-infection in Europe</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>Antitubercular Agents; Coinfection; Communicable Disease Control; data collection; Disease-Free Survival; Europe; Germany; HIV infections; Humans; Kaplan-Meier Estimate; Patient Outcome Assessment; prevalence; Proportional Hazards Models; Regression analysis; Risk; tuberculosis; Multidrug-Resistant</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The ongoing HIV epidemic and the increasing number of patients with drug-resistant tuberculosis (TB) are seriously hampering global TB-control activities, including those in the World Health Organization (WHO) Region Europe. Overall, the prevalence of HIV co-infection in TB patients increased from 3.4% in 2008 to 8% in 2014 in the region [1]. The prevalence of multidrug-resistant (MDR)-TB (drug resistance against at least isoniazid and rifampicin) reported for Europe &ndash; 15% in newly diagnosed TB patients and 48% in previously treated TB patients &ndash; is the highest in the world [1].</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-97674</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-58331</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-55626</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-93022</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-24624</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11018</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-174121</cfFedIdId>
<cfFedId>10.1183/13993003.02363-2016</cfFedId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-97674</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-97674-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Magis-Escurra</cfFamilyNames>
<cfFirstNames>Cecile</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-58331</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-58331-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Gunther</cfFamilyNames>
<cfFirstNames>Gunar</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-55626</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-55626-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Lange</cfFamilyNames>
<cfFirstNames>Christoph G.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-93022</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-93022-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Noi</cfFamilyNames>
<cfFirstNames>Autori</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-24624</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-24624-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Ciobanu</cfFamilyNames>
<cfFirstNames>Ana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11018</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11018-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Krudu</cfFamilyNames>
<cfFirstNames>V.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>